Sign Up

Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio

HOUSTON and SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million Series A financing round led by We Venture Capital and ClavystBio. The round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic's Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment. Proceeds will support expansion of Respiree's commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.

Team Respiree, with Founder and Chief Executive Officer Dr. Gurpreet Singh at Center

"The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages," said Dr. Gurpreet Singh, Founder and CEO of Respiree. "What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up."

Respiree's innovative, augmented-AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform_Accelerate program, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier, including rapid response calls in general wards and unplanned ICU transfers. Published as a pre-print in The Lancet, this flagship AI model significantly reduced false alarms while maintaining strong sensitivity, outperforming the positive predictive value (PPV) of EPIC's deterioration index by a factor of six (54.9% vs 8%). Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for its flagship AI model. The goal is to integrate the model into its platform, 1Bio™, which already incorporates data from electronic health records (EHRs), mobile ...